Investors bail on GSK following second late-stage disappointment in just weeks November 7, 2022 Investors have bailed out of GlaxoSmithKline (GSK) after the British pharmaceutical booked its second late-trial pipeline disappointment in just a few weeks. GSK’s stock price plunged more than four per cent to £13.48 per share by mid-afternoon. The firm announced this morning that its blood cancer drug Blenrep was no more effective than existing treatments. [...]
GSK lifts sales forecasts following ‘record’ success from shingles vaccine November 2, 2022 British pharmaceutical giant GlaxoSmithKline (GSK) has raised its sales forecast for the full year, on the back of the success of its shingles vaccine. Bosses at the London-listed firm now expect to deliver sales growth of between eight and ten per cent in the full-year and an adjusted operating profit of around 15 to 17 [...]
GSK steps closer to new drug milestone but R&D woes ruffle investor feathers October 31, 2022 British pharmaceutical giant GlaxoSmithKline (GSK) grew a step closer to securing its first drug approval since the split from its consumer health unit Haleon in July, but concerns over its share price remain. The US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) have agreed that the benefit of GSK’s Daprodustat, used [...]
US approval of GSK’s one-vial meningitis vaccine sweetens investors amid litigation October 17, 2022 GlaxoSmithKline’s (GSK) one-vial only meningitis vaccine Menveo has been approved by US regulators, which has sweetened investors amid its ongoing legal battle. The British medicines giant and French pharma firm Sanofi are currently undergoing a series of trials in the US over Zantac, a heartburn drug which was recalled in 2019 following claims by the US [...]
Legal woes weigh on GSK despite ‘exceptional’ trial for landmark RSV jab October 14, 2022 GlaxoSmithKline (GSK) shares slipped into the red yesterday despite “exceptional” results from the latest trial of its RSV vaccine as legal woes dampen investor confidence. The jab’s overall efficacy of 82.6 per cent was hailed as “pivotal” in finding a vaccine against RSV, which is a major cause of morbidity in toddlers and the elderly, [...]
Multi-billion FTSE newcomer Haleon shows there is life after GSK September 20, 2022 The owner of popular health products such as Sensodyne and Panadol said this a.m. its revenues have jumped up by more than 13 per cent, to a record £5.2bn, during the first half of the year. Healthcare giant Haleon further reported a double-digit hike in profits in the group’s first-ever set of company results since [...]
Changes sweep the boardrooms and C-suites of biggest businesses in the UK August 24, 2022 The boardrooms and C-suites of some of largest companies in the UK have undergone sweeping overhauls this week alone. The winds of change have blown as the country heads into autumn and buckles down for a worsening economic crisis, some two years on from the start of the pandemic. While Covid-19 measures in the country [...]
GSK shares float above recent lows amid looming legal woes August 17, 2022 British pharmaceutical giant GlaxoSmithKline (GSK) has been wrapped up with legal woes this week over recalled heartburn drug Zantac and a former AstraZeneca dealmaker – which have wiped billions off its market value. London-listed GSK’s shares have dipped into the red slightly today but remained above recent lows. However, the company has lost nearly eight [...]
UK government must wake up to clinical research slowdown, industry body warns July 31, 2022 A slowdown in clinical research could hold Britain back in its bid to become a life sciences superpower, an industry body has warned. In a letter to Rishi Sunak and Liz Truss, the Association of the British Pharmaceutical Industry (ABPI) said “alarm bells” should be ringing across the government, the Sunday Telegraph reported. The letter [...]
Ex-GSK Haleon lands on London market despite economic turbulence July 18, 2022 Haleon, GlaxoSmithKline’s (GSK) former consumer health division, will list on the London market today as a standalone entity. It is a sign of changing tides on the London Stock Exchange, which for years has heavily relied on oil, mining and financial firms. The new FTSE healthcare heavyweight, which awaits a response on its application to [...]